ECSP066362A - Inhibidores de quinesina mitótica. - Google Patents

Inhibidores de quinesina mitótica.

Info

Publication number
ECSP066362A
ECSP066362A EC2006006362A ECSP066362A ECSP066362A EC SP066362 A ECSP066362 A EC SP066362A EC 2006006362 A EC2006006362 A EC 2006006362A EC SP066362 A ECSP066362 A EC SP066362A EC SP066362 A ECSP066362 A EC SP066362A
Authority
EC
Ecuador
Prior art keywords
mythotic
kinesine
inhibitors
compounds
ksp kinesin
Prior art date
Application number
EC2006006362A
Other languages
English (en)
Inventor
Paul J Coleman
Christopher D Cox
Robert M Garbaccio
George D Hartman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP066362A publication Critical patent/ECSP066362A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a compuestos de dihidropirrol que son útiles para tratar enfermedades proliferativas celulares, para tratar trastornos asociados a la actividad quinesina KSP y para inhibir la quinesina KSP. La invención está también relacionada con composiciones que comprenden estos compuestos y procedimientos para usarlos para tratar el cáncer en mamíferos.
EC2006006362A 2003-08-15 2006-02-13 Inhibidores de quinesina mitótica. ECSP066362A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49563703P 2003-08-15 2003-08-15
US51268003P 2003-10-20 2003-10-20
US56358604P 2004-04-19 2004-04-19

Publications (1)

Publication Number Publication Date
ECSP066362A true ECSP066362A (es) 2006-10-31

Family

ID=34222358

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006362A ECSP066362A (es) 2003-08-15 2006-02-13 Inhibidores de quinesina mitótica.

Country Status (13)

Country Link
US (1) US20050038074A1 (es)
KR (1) KR20060058716A (es)
AR (1) AR045342A1 (es)
BR (1) BRPI0413580A (es)
CO (1) CO5650252A2 (es)
EC (1) ECSP066362A (es)
IL (1) IL173513A0 (es)
IS (1) IS8276A (es)
MA (1) MA27986A1 (es)
NO (1) NO20061194L (es)
PE (1) PE20050730A1 (es)
TW (1) TW200510380A (es)
WO (1) WO2005019205A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003276005B2 (en) 2002-06-14 2009-01-15 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
IL165624A0 (en) 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors
US7638549B2 (en) 2003-08-15 2009-12-29 Merck & Co. Inc. Mitotic kinesin inhibitors
CA2533889A1 (en) 2003-08-15 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
US7465746B2 (en) * 2003-08-15 2008-12-16 Merck & Co., Inc. Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP
EP1740537A2 (en) * 2004-04-19 2007-01-10 Merck & Co., Inc. A process for the preparation of 2,2-disubstituted pyrroles
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7723330B2 (en) 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
WO2009052288A1 (en) 2007-10-19 2009-04-23 Schering Corporation Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
CA3107770C (en) 2018-08-16 2023-09-05 Emd Millipore Corporation Closed bioprocessing device
EP4076459B1 (en) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5 inhibitors
ES3074517T3 (en) 2019-12-17 2026-07-21 Merck Sharp & Dohme Llc 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
DE212025000115U1 (de) 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6440686B1 (en) * 2000-06-15 2002-08-27 Cytokinetics, Inc. Methods for screening and therapeutic applications of kinesin modulators
CA2467916A1 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003276005B2 (en) * 2002-06-14 2009-01-15 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
IL165624A0 (en) * 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors
US7235580B2 (en) * 2002-10-18 2007-06-26 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
BRPI0413580A (pt) 2006-10-17
AR045342A1 (es) 2005-10-26
US20050038074A1 (en) 2005-02-17
CO5650252A2 (es) 2006-06-30
MA27986A1 (fr) 2006-07-03
PE20050730A1 (es) 2005-09-20
KR20060058716A (ko) 2006-05-30
IS8276A (is) 2006-01-31
NO20061194L (no) 2006-05-05
WO2005019205A1 (en) 2005-03-03
TW200510380A (en) 2005-03-16
IL173513A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
ATE446094T1 (de) Mitotische kinesin-hemmer
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
ATE448207T1 (de) Mitotische kinesin-hemmer
EP1515949A4 (en) INHIBITORS OF MITOTIC KINESINE
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
EP1463733A4 (en) INHIBITORS OF MITOTIC KINESINE
WO2004037171A3 (en) Mitotic kinesin inhibitors
WO2005017190A3 (en) Mitotic kinesin inhibitors
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2004058148A3 (en) Mitotic kinesin inhibitors
TW200510380A (en) Mitotic kinesin inhibitors
WO2005060654A3 (en) Mitotic kinesin inhibitors
NO20070589L (no) Mitotiske kinesin-inhibitorer.
EP1635641A4 (en) INHIBITORS OF MITOTIC KINESINE
WO2006007496A3 (en) Mitotic kinesin inhibitors
DOP2004000974A (es) Inhibidores de la quinesina mitotica
WO2004087050A3 (en) Mitotic kinesin inhibitors